Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00814255 · ClinicalTrials.gov registry record · Phase 2
Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00814255 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 32 participants.
The verdict
NCT00814255, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This project will test whether adalimumab,and/or galactose can safely reduce proteinuria (abnormal amounts of protein in the urine) and protect kidney function better than standard treatment for patients with focal segmental glomerulosclerosis (FSGS).
Interventions
- DRUG Adalimumab
- DRUG Lisinopril, losartan, and atorvastatin
- DRUG galactose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2008-12 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00814255
The ClinicalTrials.gov registry entry for NCT00814255 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Adalimumab is the first listed.
NCT00814255 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00814255 about?
NCT00814255 is a clinical study titled "Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial". This project will test whether adalimumab,and/or galactose can safely reduce proteinuria (abnormal amounts of protein in the urine) and protect kidney function better than standard treatment for patients with focal segmental glomerulosclerosis (FSGS).
What is the current status of trial NCT00814255?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2008-12. Estimated completion is 2014-02.
What interventions are being tested in trial NCT00814255?
The interventions under investigation include: Adalimumab (DRUG), Lisinopril, losartan, and atorvastatin (DRUG), galactose (DRUG).
Who is sponsoring clinical trial NCT00814255?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.